Where does CTOR stock trade?

Citius Oncology Inc. (CTOR) is listed on NASDAQ.

What sector and industry is CTOR in?

Citius Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Citius Oncology Inc. go public?

Citius Oncology Inc. (CTOR) completed its IPO in 2022.

What are analysts saying about CTOR?

Citius Oncology Inc. has had 2 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $600.00 price target on 2025-09-23. Recent price targets range from $300.00 to $600.00.

What companies are similar to CTOR?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CTOR side-by-side with any of them on Quantisnow.

How can I track CTOR on Quantisnow?

Quantisnow aggregates Citius Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTOR to receive live email and push alerts on every new disclosure.

CTOR

NASDAQ

Citius Oncology Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2022

News25/Ratings2

News · 26 weeks41+1100%

2026-03-012026-08-23

Mix2090d

SEC Filings10(50%)
Other7(35%)
Leadership1(5%)
Offering1(5%)
Insider1(5%)

Latest news

25 items

11dINSIDER
New insider Peri Jonathan claimed no ownership of stock in the company (SEC Form 3)
3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
11dSEC
SEC Form 424B3 filed by Citius Oncology Inc.
424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
11dSEC
Citius Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
11dSEC
SEC Form 10-Q filed by Citius Oncology Inc.
10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
11dPR
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR® launch progressesStrong institutional demand drives growth in total vials ordered and number of institutions orderingLYMPHIR ordered by 44 institutions since launchCRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update. "Institutional
11dPR
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical affairs organizations deployed nationwideCRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (NASDAQ:CTOR)."The LYMPH
11dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Citius Oncology Inc.
SCHEDULE 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
13dSEC
Citius Oncology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
13dPR
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D., J.D., as an additional independent director, effective August 10, 2026. Following a unanimous vote of approval by the Board, the appointment expands the Company's Board of Directors to nine members. Dr. Peri brings three decades of leadership across higher education, financial services, law, and corporate g
20dSEC
SEC Form 424B3 filed by Citius Oncology Inc.
424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
20dSEC
Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
20dPR
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-universal payer coverage expands market accessInitial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 millionCRANFORD, N.J., Aug. 5, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority U.S. treatment centers, and other key indicators supportin
35dPR
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today provided an update on the commercial launch of LYMPHIR® (denileukin diftitox-cxdl), highlighting continued progress across market access, commercial execution, and physician adoption. Citius Oncology has expanded its commercial organization to include 21 additional commercial
78dSEC
SEC Form EFFECT filed by Citius Oncology Inc.
EFFECT - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
82dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Citius Oncology Inc.
SCHEDULE 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
85dSEC
SEC Form 424B3 filed by Citius Oncology Inc.
424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
85dSEC
Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
85dPR
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated patients20.5 months of median progression-free survival observed among 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21) Responses were observed in patients previously treated with immune checkpoint inhibitors, including a 33% objective response rate in patients with relapsed or refractory endometrial cancerCRANFORD, N.J., June 1, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑
88dSEC
SEC Form DEF 14C filed by Citius Oncology Inc.
DEF 14C - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
88dSEC
SEC Form S-3 filed by Citius Oncology Inc.
S-3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
91dPR
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Investigator-initiated study of LYMPHIR in combination with pembrolizumab to be presented during immunotherapy session, highlighting potential role of LYMPHIR beyond CTCLCRANFORD, N.J., May 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that University of Pittsburgh Medical Center's investigator-initiated
95dSEC
SEC Form 424B3 filed by Citius Oncology Inc.
424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
98dSEC
SEC Form PRE 14C filed by Citius Oncology Inc.
PRE 14C - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
102dSEC
Citius Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
102dSEC
SEC Form 10-Q filed by Citius Oncology Inc.
10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

CTOR FAQ

6 questions

Where does CTOR stock trade?
Citius Oncology Inc. (CTOR) is listed on NASDAQ.
What sector and industry is CTOR in?
Citius Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Citius Oncology Inc. go public?
Citius Oncology Inc. (CTOR) completed its IPO in 2022.
What are analysts saying about CTOR?
Citius Oncology Inc. has had 2 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $600.00 price target on 2025-09-23. Recent price targets range from $300.00 to $600.00.
What companies are similar to CTOR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CTOR side-by-side with any of them on Quantisnow.
How can I track CTOR on Quantisnow?
Quantisnow aggregates Citius Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTOR to receive live email and push alerts on every new disclosure.